STOCK TITAN

GSK (NYSE: GSK) president acquires notional ADS in executive savings plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

GSK plc reported that senior executive Maya Martinez-Davis acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account. The transaction involved 8.955 notional ADS at a price of $53.3200 per ADS on 7 July 2026, executed on the New York Stock Exchange.

Positive

  • None.

Negative

  • None.
Notional ADS acquired 8.955 ADS GSK Executive Supplemental Savings Plan account
Transaction price $53.3200 per ADS Price of notional ADS credited to plan
Transaction date 2026-07-07 Date of notional ADS acquisition
PDMR regulatory
"Details of PDMR/person closely associated with them ('PCA')"
A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.
American Depositary Shares financial
"Description of the financial instrument | American Depositary Shares ('ADS')"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Executive Supplemental Savings Plan financial
"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account"
LEI regulatory
"b) | LEI | 5493000HZTVUYLO1D793"
A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did GSK (GSK) disclose in this report?

GSK disclosed that executive Maya Martinez-Davis acquired notional American Depositary Shares in her Executive Supplemental Savings Plan account. The transaction was reported as an acquisition of plan-linked notional ADS rather than a standard open-market share purchase.

Who is the GSK (GSK) executive involved in the July 2026 transaction?

The executive is Maya Martinez-Davis, identified as a President at GSK. She is classified as a PDMR, meaning a person discharging managerial responsibilities, and her transaction must be disclosed under market abuse and transparency regulations.

What exactly did Maya Martinez-Davis acquire in the GSK (GSK) plan?

She acquired notional American Depositary Shares credited within her GSK Executive Supplemental Savings Plan account. These are plan-based notional holdings, linked to GSK ADS value, instead of a direct open-market purchase of regular ADS in a brokerage account.

What were the price and volume of the GSK (GSK) notional ADS transaction?

The transaction covered 8.955 notional American Depositary Shares at a price of $53.3200 per ADS. It is recorded as a single transaction, with no aggregated multi-trade breakdown, within the executive supplemental savings plan structure.

When and where was the GSK (GSK) transaction carried out?

The notional ADS acquisition was dated 7 July 2026 and is stated as having been conducted on the New York Stock Exchange. This location reference aligns the plan-linked notional ADS with the exchange where GSK ADS are listed and traded.

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
GSK plc (the 'Company') 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Maya Martinez-Davis
 
b)
Position/status
President, US
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADS')
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$53.3200
8.9550
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
2026-07-07
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
Registered in England & Wales:
No. 3888792
 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 09, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc